Bevacizumab (BEV) and risk of hemorrhage (HEM) in metastatic castration-resistant prostate cancer (mCRPC) patients treated on CALGB 90401 (Alliance).
- Citation:
- J Clin Oncol vol 32 (15_suppl) e16061
- Meeting Instance:
- ASCO 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Published Only
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- Jai Narendra Patel Chen Jiang Daniel Louis Hertz Flora Mulkey Paula N. Friedman Susan Halabi Mark J. Ratain Michael J. Morris Eric Jay Small Kouros Owzar William Kevin Kelly Howard L. McLeod
- Networks:
- Study
- CALGB-90401
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: